oxygen/nitrous oxide mixture (1:2) and local anaesthetic infiltration. All animals 25 received a loading dose (1.67 mg kg -1 minute -1 ) for 2.5 minutes followed by a constant 26 rate infusion (0.75 mg kg -1 minute -1 ) for 120 minutes of alfaxalone. Isoflurane and 27 nitrous oxide was discontinued 2.5 minutes after the alfaxalone infusion started. 28
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Animals Twelve (six male and six female) adult, aged matched Sprague Dawley rats. 23
Methods Surgery and instrumentation was performed under isoflurane anaesthesia in an 24
oxygen/nitrous oxide mixture (1:2) and local anaesthetic infiltration. All animals 25 received a loading dose (1.67 mg kg -1 minute -1 ) for 2.5 minutes followed by a constant 26 rate infusion (0.75 mg kg -1 minute -1 ) for 120 minutes of alfaxalone. Isoflurane and 27 nitrous oxide was discontinued 2.5 minutes after the alfaxalone infusion started. 28
Cardiorespiratory variables (heart rate, respiratory rate, arterial blood pressure, end tidal 29 carbon dioxide tension) and clinical signs of anaesthetic depth were evaluated 30 throughout anaesthesia. Carotid artery blood samples were collected at strategic time 31
points for blood gas analysis, haematology and biochemistry and plasma concentrations 32 of alfaxalone. Plasma samples were assayed using liquid chromatography-mass 33 M A N U S C R I P T
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Sex-based differences in pharmacokinetics and pharmacodynamics were demonstrated 40 and must be considered when designing biomedical research models using alfaxalone. 41
Introduction 45
Alfaxalone is a neuroactive steroid that modulates neurotransmission through 46 interaction with a steroid recognition site on the GABA A receptor complex causing a 47 M A N U S C R I P T
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7 surgically cannulated using 1mm O.D. polyethylene tubing (Fisher Scientific) to 114 monitor arterial blood pressure and for sampling. Arterial blood pressure was monitored 115
by an arterial pressure transducer (SensoNor 840; SensoNor, Norway) and recorded 116 using a PC running Spike2 software (CED Ltd, UK). Heart rate was recorded via two 25 117 gauge needles inserted subcutaneously on the lateral sides of the thoracic wall. The 118 electrocardiogram signal was amplified and used to trigger an instant rate meter 119 (Neurolog NL253, Digitimer, UK) and again recorded using Spike2 software. 120
An infusion of alfaxalone (Alfaxan, Jurox, UK) was started at time 0 at a loading dose 121 of 1.67 mg kg -1 minute -1 for 2.5 minutes followed by a constant rate infusion (0.75 mg 122 kg -1 minute -1 ) for the remainder of the electrophysiological experiment using a 123 calibrated syringe driver (SP100iz, WPI, UK). The isoflurane and nitrous oxide were 124 stopped 2.5 minutes after starting the alfaxalone infusion. Arterial blood was withdrawn 125 from the carotid cannula into lithium heparin and placed on ice. Blood samples (200µl) 126 were collected at baseline (prior to alfaxalone), end of loading dose, and at 10, 30, 60, 127 90, 120 minutes. Arterial blood gases, biochemistry and haematology parameters (pH, 128 pCO 2 , pO 2 , bicarbonate, sodium, potassium, chloride, calcium, glucose, lactate and 129 creatinine concentrations) were also measured (EPOC, Woodley Instrumentation, 130 Bolton, Lancashire, UK). All rats received an equal volume of balanced electrolyte 131 solution after sampling (Vetivex 11 (Hartmann's); Dechra, UK). Samples were 132 centrifuged (4000g for 10 minutes) within 30 minutes of collection. Plasma was 133 harvested and stored at -20°C until determination of plasma alfaxalone concentration. Following the pharmacokinetic study, a separate electrophysiological study was 138 performed, EMG responses were recorded from tibialis anterior, biceps femoris, and 139 medial gastrocnemius muscles during electrical plantar hind paw stimulation of the toes 140 and heel, before and after a conditioning injection of capsaicin into either the 141 contralateral forelimb to study diffuse noxious inhibitory controls (DNIC) or the 142 ipsilateral hind limb to investigate central sensitization and reflex facilitation (Harris & 143 Clarke 2003) . Data from this part of the study were not included in this paper but 144 informed the subjective assessment of response to noxious stimuli during alfaxalone 145 anaesthesia. At the end of the experiments animals were euthanised by IV injection of 146 pentobarbitone (Pentobarbital; Ayrton Saunders Ltd, UK) followed by cervical 147 dislocation (as required by UK Home Office regulations). All female rats underwent 148 vaginal swabbing to characterise vaginal smear cell types. Slides were examined under 149 x40 and then x100 magnifications (BH2 microscope, Olympus, UK) after staining with 150 modified Giemsa (Diff Quik, Vet Direct, UK) and cell types and numbers were 151
recorded. 152 153

Sample analyses 154
Samples were analyzed for alfaxalone using a LCMS/MS method. Methanolic standard 155 curve and quality control (QC) spiking solutions were produced for alfaxalone from 156 separate accurate weighings of solid compound. Standards and QCs were prepared by 157 spiking 10 µl spike solution into a solution of 20 µl plasma + 30 µl water + 40 µl 158 methanol + 150 µl methanol containing 1000 nM tolbutamide as internal standard.
Plasma standard curves were prepared from 100 -5000 ng mL -1 and QCs were prepared 160 for 250 and 2500 ng mL -1 . Blank male or female plasma was used for the standards and 161 QC solutions (Charles River, UK). The plasma samples were prepared by adding 30 µl 162 water + 50 µl methanol + 150 µl methanol containing 1000 nM tolbutamide as internal 163 standard to 20 µl plasma. Samples, standards and QCs were then mixed and stored in a 164 freezer at -20°C for a minimum of 120 minutes prior to centrifugation at 4000g for 20 165 minutes. The samples were extracted and analyzed using a Micromass Quattro Premier 166 mass spectrometer incorporating an Acquity autosampler (Waters, UK). An ACE Excel 167 2 C18-AR 50 x 2.1mm column was used with the following LC conditions: Solvent A = 168 Cardiopulmonary data were collected continuously, and analyzed at the 197 pharmacokinetic time points. The normality assumptions were tested with Smirnov or Shapiro-Wilk tests. The differences in heart rate, mean/systolic/diastolic 199 arterial blood pressure, blood gas variables, lactate, glucose and electrolytes between 200 genders were compared using an unpaired t-test. consisting of a 120 minutes of a PK/PD study followed by an electrophysiology study. 210
Only results from the former are reported here. 211
212
Pharmacokinetics 213 The shape of the concentration-time curve following a loading dose and then constant 214 rate infusion was typical of those observed for anaesthetic induction drugs exhibiting an 215 initial steep phase after the loading dose followed by a gradual increase until steady 216 state was achieved. The plasma concentrations were substantially different between the 217 sexes ( Figure 1) . 218
The pharmacokinetic parameters calculated by an IV infusion one compartmental model 219 are shown in Table 1 . Logarithmic transformed data for clearance and t 1/2 was 220 significantly different between the male and female rats by the two-tailed t-test. As 221 would be expected the MRT was also significantly different between genders. 222
After a 2.5 minute loading dose all rats showed an initial short lived decrease in arterial 226 blood pressure, heart rate and respiratory rate as a result of concomitant administration 227 of inhalant and alfaxalone. Within the next 5 minutes following discontinuation of 228 isoflurane, all rats demonstrated an increase in blood pressure from baseline reading 229 under isoflurane and nitrous oxide anaesthesia. Blood pressure (mean, systolic, 230 diastolic), heart rate and respiratory rate at baseline were not significantly different 231 between male and female rats under isoflurane anaesthesia. 232
Heart rates remained stable during alfaxalone anaesthesia and there was no significant 233 difference between the sexes at any time points. 234
Systolic, mean and diastolic arterial pressures all increased from baseline under 235 isoflurane anaesthesia, reached a peak (between 60 and 90 minutes) and thereafter 236
showed a trend of decreasing with time. Mean arterial blood pressure was significantly 237 different between males and female rats (p = 0.026), however the interaction with time 238 (p < 0.0001) differed between the genders for mean (and systolic and diastolic) pressure 239 and makes the interpretation of these data difficult (Fig. 2 ). Significant differences were 240 analyzed post hoc using Sidak' multiple comparison test. Mean arterial blood pressure 241 was significantly increased compared to baseline in male rats at 30, 60, 90 and 120 242 minutes from starting the alfaxalone (p < 0.0005), as were systolic and diastolic 243 pressures. Mean arterial blood pressure was only significantly greater than baseline in 244 the female rats at 60 minutes. In 4 of 12 animals (2 males and 2 females) 245 cardiopulmonary depression, indicated by a decrease in blood pressure or respiratory 246 rate, necessitated discontinuation of the isoflurane and nitrous oxide before the 2.5M A N U S C R I P T
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13 minute time point. Within 60 seconds of discontinuation of the isoflurane and nitrous 248 oxide, heart rate and blood pressure began to rise in all animals. 249
All female rats ventilated spontaneously throughout the experiment, whereas 2 of 6 250 male rats required mechanical ventilation as judged by apnoea, or a rise in end tidal 251 carbon dioxide coupled with a decrease in respiratory rate and effort. 252
Blood gas parameters and biochemistry values are presented in Table 3 . There were no 253 significant differences between sexes for these parameters except for pH (p = 0.0027), 254 which was lower in the female rats in conjunction with higher partial pressures of 255 carbon dioxide. The clinical significance of this is unknown and of little significance. 
Hypnotic effect 261
The plane of anaesthesia was continually evaluated by serial cardiopulmonary 262 measurements, blood gas analysis and reflex responses. Subjective evaluation of this 263 hypnotic effect of the alfaxalone in all 12 rats was excellent. No rats demonstrated gross 264 purposeful movement or required a change in the infusion rate to improve the plane of 265
The same investigator read all slides (3 per rat) and evaluated the whole slide to give an 269 impression of the smear, rather than exact cell counts. Three rats were characterized as 270 in dioestrus, one in proestrus, one in oestrus, and one in metoestrus. 271
Discussion 272
The major finding from this study is that consideration must be given to the dose of 273 anaesthetic delivered to male and female subjects. Without this interrogation of the 274 experimental model there remains the danger that studies will be carried out under what 275 is assumed to be identical 'planes' of anaesthesia, when in reality one sex may be more 276 or less profoundly anaesthetized such that, for example, hormonal or neuroendocrine 277 responses will be affected. 278
The data reported here were part of an electrophysiological study investigating diffuse 279 noxious inhibitory controls of nociceptive withdrawal reflexes and is part of a larger 280 study of descending control in chronic osteoarthritis, which in humans is more prevalent 281 in females, and highlights the potential risk that using one sex may contribute to the 282 failure of Phase 1 trials or misleading conclusions. In many studies, the influence of the 283 anaesthetic is ignored, or so poorly reported that ensuring a consistent plane of 284 anaesthesia is impossible. Although rats are frequently used in laboratory studies 285 involving anaesthesia, it is typically males used to reduce experimental variability 286 Commendably, there is a movement towards trying to include more female subjects in 295 studies. 296
The small sample size in our study makes it impossible to postulate that differences 297 within the females are a result of the differences in the oestrous cycle or as a result of 298 normal variability; nonetheless it demonstrates that if steroid hormones can affect 299 alfaxalone efficacy, the stage of the oestrous cycle may also contribute. It is possible 300 that the three female rats requiring additional isoflurane for several minutes between 301 minute 6 and 10 after commencing the alfaxalone may be a result of the stage of the 302 oestrous cycle, but this is impossible to prove definitively. 303
In the research community there remains a collective responsibility for a thoroughness 304 of reporting anaesthesia conditions in order that the anaesthesia is not 'the elephant in 305 the room'. volume and differential perfusion of organs. However, in this study no significant 320 difference was recorded between male and female Vss suggesting this was not an issue. 321
In general, however, sex differences in metabolism are thought to be the primary 322 determinant of variation in pharmacokinetics and this is most likely the reason for the 323 differences seen in this study. 324
325
The quality of anaesthesia was subjectively judged as excellent in all rats. Contrary to 326 previous studies (Brammer et al. 1993) , this anaesthetic combination provided very 327 good conditions, stability and survival beyond 180 minutes. The lower blood pressures 328 observed in female rats in this study would suggest that these animals were more 329 profoundly anaesthetized than the males. There was no difference in heart rates between 330 the groups, and the depth of anaesthesia was not so sufficiently profound as to cause 331 apnoea in the females. This is likely to be a pharmacokinetic effect as the females' 332 clearance of alfaxalone is so much less than in the male rats. The consistency of theM A N U S C R I P T
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17 haematology, biochemistry and blood gas values in all rats demonstrates the stability of 334 the protocol. Blood gas values are infrequently reported for rodent anaesthetics, in part 335 due to the technical nature of artery cannulation, and previously the volume of blood 336 required made repeated sampling impossible due to a deleterious depletion of the blood 337 volume of the animal. Newer point of care analyzers are able to process much smaller 338 volumes. Total blood volume removed was well below the limit of 10% blood volume 339 and this removal of blood in conjunction with a replenishment of balanced electrolyte 340 solution clearly had no impact on the animals. All biochemistry and haematology values 341 except chloride were similar to those provided by the supplier of the Sprague Dawley 342 rats in age-matched subjects. Invariably these samples were analysed with different 343 machines, but even with slight discrepancies usually seen between laboratories, plasma 344 chloride values in the study (mmol L -1 ) (114 ± 2.6 (females) 115 ± 2.7 (males)) and 345 values in age matched conscious Sprague Dawley rats (109 ± 1.4 (females), 103 ± 1.00 346 and female rats has been demonstrated, with males requiring four times the dose of 361 females for surgical anaesthesia and analgesia, and it was concluded that the influence 362 of sex hormones was responsible for this discrepancy (Fink et al. 1982) . However a 363 recent study disputed this and postulated that differences are more likely a result of the 364 different formulations of alfaxalone and assay methodologies than differences between 365 sexes (Lau et al. 2013) . Notwithstanding these views it has also been shown that 366 formulation is hugely influential; the toxicity of alfaxalone in Wistar rats was less in 367 those animals receiving alfaxalone dissolved in 7-sulfobutyl-ether-β-cyclodextrin 368 (SBECD) compared to alfaxalone in Cremophor EL (Goodchild et al. 2015 ). The 369 current study directly comparing male and female Sprague Dawley rats receiving an 370 HPCD alfaxan formulation seemingly favours a true sex difference due to 371 pharmacokinetics, pharmacodynamics or both as the explanation. Sex based studies 372 using rats anaesthetized with pentobarbitone have also demonstrated differences 373
(Zambricki & Dalecy 2004). Sex differences have been detected in studies comparing 374
IP and IV routes in rats (Estes et al. 1990 ) postulating that the lack of obvious sex 375 differences with single IV dosing may be a result of the short duration of effect. 376
Group sizes of 6 were deemed appropriate for evaluating a drug exhibiting within 377 subject variability of less than 30% coefficient of variation of pharmacokineticM A N U S C R I P T
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19 of anaesthetic drugs have successfully used 5 rats per group (Bencze et al. 2013) . It 380 should also be noted that the presence of isoflurane and nitrous oxide at the outset of the 381 loading dose is likely to have affected cardiopulmonary parameters in the very early 382 stages of the infusion and conclusions drawn about differences at these time points are 383 likely to be tenuous. However both groups underwent identical protocols so this 384 influence would have been similar for both groups. The use of an inhalational agent 385 such as isoflurane with minimal metabolism and rapid elimination ensured that the 386 period of time from ceasing administration was as short as possible. The maximum 387 possible duration of initial concurrent administration was 2.5 minutes. 388
389
In summary, there are pharmacokinetic and pharmacodynamic differences with 390 alfaxalone in cyclodextrin in male and female rats. The plane of anaesthesia provided 391 by this protocol is stable and clinically indistinguishable between sexes with no 392 apparent cumulative effect. Half-life, clearance and mean residence time were 393 significantly different between male and female rats indicating that a sex-linked effect 394 was present. The protocol in our study provides excellent anaesthesia conditions but 395 concludes that a dose alteration may be necessary for rat sex-based studies 396 incorporating alfaxalone. This contrasts to previous published studies, which have 397 dismissed a sex difference (Ferré et al. 2006; Berry 2015) . Population pharmacokinetics 398 are necessary to further investigate these findings. Dawley rats (6 female, 6 male) after intravenous administration of alfaxalone 1.67 mg 552 kg -1 minute -1 for 2.5 minutes followed by 0.75 mg kg -1 minute -1 alfaxalone for 120 553 minutes using a one compartment infusion model. 554 Asterisks denote significant difference *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 573 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT Table 2 Cardiopulmonary parameters for 12 Sprague Dawley rats (6 female, 6 male) after intravenous administration of 575 alfaxalone at a rate of 1.67 mg kg -1 minute -1 for 2.5 minutes followed by 0.75 mg kg -1 minute -1 for 120 minutes using a one 576 compartment infusion model. ) for 12 Sprague Dawley rats (6 female, 6 male) after intravenous administration of alfaxalone 1.67 mg kg -1 min -1 for 2.5 minutes followed by 0.75 mg kg -1 min -1 alfaxalone for 120 minutes using a one compartment infusion model. 
